Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18149195 | 1.00 | JAK2 (0.45) | JAK2JAK1GPR119STSPARP1 | |
| SCHEMBL16836138 | 0.82 | ALDH1A1 (0.42) | CYP2C9SMN1; SMN2 | |
| SCHEMBL27534101 | 0.80 | ESR2 (0.47) | JAK2JAK1GPR119STSKDM4E | |
| SCHEMBL7433532 | 0.77 | JAK2 (0.48) | JAK2JAK1GPR119STSUSP30 | |
| SCHEMBL18484113 | 0.77 | HSD11B1 (0.45) | JAK2JAK1GPR119STSKDM4E | |
| SCHEMBL2817602 | 0.76 | ESR2 (0.43) | JAK2JAK1GPR119STSUSP30 | |
| SCHEMBL994232 | 0.76 | ESR2 (0.43) | JAK2JAK1GPR119STSUSP30 | |
| SCHEMBL24326305 | 0.75 | PARP1 (0.53) | JAK2JAK1GPR119STSPARP1 | |
| SCHEMBL8466304 | 0.74 | NAMPT (0.44) | JAK2JAK1GPR119STSKDM4E | |
| SCHEMBL2707159 | 0.74 | DDB1 (0.49) | JAK2JAK1GPR119STSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083573-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-10000484-B2 | Inhibitors of the renal outer medullary potassim channel | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3083573-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160304515-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
| WO-2015095097-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000484-B2 | Inhibitors of the renal outer medullary potassim channel | KCNJ11, KCNJ1, KCNJ2 | JAK2 1557/4885JAK1 1427/4885GPR119 774/4885 |
| US-20160304515-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | JAK2 1557/4885JAK1 1427/4885GPR119 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.